CTNM
Contineum Therapeutics, Inc.Company Information
- Company Name
- Contineum Therapeutics, Inc.
- CIK
- CIK0001855175
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- CTNM: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CTNM
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-08
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 84,158
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 30,726,147
- Shares outstanding
- 37,467,840
- Ownership
- 82.01%
Earnings Market Reaction
- Filing date
- 2026-07-30
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Class A | 0 | 33 | 0 | - | -19 | 19 | 0 | - | - | - | ||||||
| Common Class B | 0 | 5 | 0 | - | 0 | 7 | 0 | - | - | - | ||||||
Assets | ||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 15 | 20 | 76 | 43 | 21 | 22 | 22 | 41 | 77 | 16 | ||||||
Assets Current | ||||||||||||||||
| Assets Current | 243 | 253 | 268 | 185 | 177 | 192 | 206 | 215 | 220 | 120 | ||||||
| Marketable Securities Current | 222 | 226 | 187 | 140 | 155 | 168 | 183 | 173 | 141 | 102 | ||||||
| Prepaid Expense And Other Assets Current | 6 | 7 | 5 | 3 | 1 | 1 | 2 | 1 | 2 | 2 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | ||||||
| Operating Lease Right Of Use Asset | 6 | 7 | 2 | 5 | 5 | 5 | 5 | 6 | 0 | 0 | ||||||
| Assets | 250 | 261 | 277 | 191 | 183 | 198 | 213 | 216 | 221 | 124 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 1 | ||||||
Liabilities Current | ||||||||||||||||
| Liabilities Current | 7 | 7 | 10 | 6 | 7 | 9 | 10 | 6 | 4 | 6 | ||||||
| Accrued Liabilities Current | 4 | 3 | 6 | 4 | 4 | 4 | 7 | 4 | 3 | 5 | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 4 | 5 | 6 | 4 | 4 | 5 | 5 | 0 | 0 | 0 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | 0 | 0 | 0 | 193 | ||||||
| Common Stock Value | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Liabilities | 11 | 11 | 16 | 10 | 11 | 13 | 15 | 6 | 4 | 7 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Additional Paid In Capital | 447 | 442 | 438 | 342 | 321 | 318 | 315 | 312 | 310 | 8 | ||||||
Stockholders Equity | ||||||||||||||||
| Stockholders Equity | 240 | 250 | 261 | 180 | 171 | 185 | 198 | 210 | 218 | -76 | ||||||
| Retained Earnings Accumulated Deficit | -207 | -192 | -177 | -162 | -149 | -133 | -117 | -103 | -93 | -84 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | 0 | 0 | 0 | 0 | 0 | 1 | -0 | -0 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | - | - | - | - | - | - | - | - | - | 220 | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | 0 | 0 | 0 | 17 | ||||||
| Liabilities And Stockholders Equity | 250 | 261 | 277 | 191 | 183 | 198 | 213 | 216 | 221 | 124 | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | 0 | 0 | 0 | 16 | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | 0 | 0 | 0 | 16 | ||||||
| Temporary Equity Liquidation Preference | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Common Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | 0.00 | ||||||
| Common Stock Shares Issued | - | - | - | - | - | - | - | - | - | 2 | ||||||
| Shares Outstanding | - | - | - | - | - | - | - | - | - | 2 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialContineum Therapeutics, Inc. (CTNM) — SEC Financial Statements & Analysis
Contineum Therapeutics, Inc. (CTNM) is a pharmaceutical preparations company, incorporated in DE. Contineum Therapeutics, Inc. trades on Nasdaq as: CTNM. Contineum Therapeutics, Inc. (CTNM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30. Based on that filing, Contineum Therapeutics, Inc. carries a market cap of $614.10M, a P/E ratio of -10.67x, a P/B ratio of 2.56x, an enterprise value of $599.39M, and an EV/EBITDA multiple of -9.08x. On profitability, it posts a Return on Equity (ROE) of -28.01%, a Return on Assets (ROA) of -26.57%, and a Return on Invested Capital (ROIC) of -35.35%. Per share, it reports EPS of $-1.54, diluted EPS of $-1.54, free cash flow per share of $-1.43, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 1.22% year-over-year and EPS growth of -30.04% year-over-year. On the balance sheet, it maintains a current ratio of 37.17x, a quick ratio of 36.25x, working capital of $236.05M, a debt-to-equity ratio of 0.04x, a debt ratio of 0.04, free cash flow of $-53.46M (TTM), and net debt of $-14.71M. Figures sourced from SEC EDGAR.
- Market Cap
- $614.10M
- P/E TTM
- -10.67x
- EPS TTM
- $-1.54
- P/B TTM
- 2.56x
- ROE TTM
- -28.01%
- ROA TTM
- -26.57%
- Debt To Equity
- 0.04x
- Free Cash Flow TTM
- $-53.46M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Contineum Therapeutics, Inc. in?
Contineum Therapeutics, Inc. (CTNM) operates in the Pharmaceutical Preparations industry.
What exchange does CTNM trade on?
Contineum Therapeutics, Inc. (CTNM) trades on the Nasdaq.
Where is Contineum Therapeutics, Inc. incorporated?
Contineum Therapeutics, Inc. is incorporated in DE.
When was Contineum Therapeutics, Inc. (CTNM)'s most recent SEC filing?
Contineum Therapeutics, Inc. (CTNM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30.
What is CTNM's market cap?
Contineum Therapeutics, Inc. (CTNM) has a market capitalization of $614.10M as of 2026-06-30.
What is CTNM's EPS (earnings per share)?
Contineum Therapeutics, Inc. (CTNM)'s trailing twelve month EPS is $-1.54 as of 2026-06-30.
What is CTNM's ROE (return on equity)?
Contineum Therapeutics, Inc. (CTNM)'s trailing twelve month Return on Equity (ROE) is -28.01% as of 2026-06-30.
What is CTNM's ROA (return on assets)?
Contineum Therapeutics, Inc. (CTNM)'s trailing twelve month Return on Assets (ROA) is -26.57% as of 2026-06-30.
What is CTNM's ROIC (return on invested capital)?
Contineum Therapeutics, Inc. (CTNM)'s trailing twelve month Return on Invested Capital (ROIC) is -35.35% as of 2026-06-30.
What is CTNM's EV/EBITDA?
Contineum Therapeutics, Inc. (CTNM)'s trailing twelve month EV/EBITDA is -9.08x as of 2026-06-30.